1-4 of 4
Tadashi Honjo
Close
Sort by
Journal Articles

Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation

Yuko Hiruma, Tadashi Honjo, Diane F. Jelinek, Jolene J. Windle, Jaekyoon Shin, G. David Roodman, Noriyoshi Kurihara
Journal: Blood
Blood (2009) 113 (20): 4894–4902.
https://doi.org/10.1182/blood-2008-08-173948
Published: 2009
Includes: Supplemental data
Journal Articles

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1

Gülsüm Anderson, Margarete Gries, Noriyoshi Kurihara, Tadashi Honjo, Judy Anderson, Vera Donnenberg, Albert Donnenberg, Irene Ghobrial, Markus Y. Mapara, David Stirling, David Roodman, Suzanne Lentzsch
Journal: Blood
Blood (2006) 107 (8): 3098–3105.
https://doi.org/10.1182/blood-2005-08-3450
Published: 2006
Includes: Supplemental data
Journal Articles

Thalidomide Derivative CC-4047 Inhibits Osteoclast Formation by down Regulation of PU.1.

Suzanne Lentzsch, MD, PhD, Gulsum Anderson, PhD, Noriyoshi Kurihara, DDS, PhD, Tadashi Honjo, DDS, PhD, Judith Anderson, Markus Y. Mapara, MD, PhD, David Stirling, PhD, David Roodman, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 629.
https://doi.org/10.1182/blood.V106.11.629.629
Published: 2005
Journal Articles

Targeting p62 ZIP in Marrow Stromal Cells Is Highly Effective at Inhibiting Myeloma Cell Growth and Osteoclast Formation.

Noriyoshi Kurihara, DDS, PhD, Tadashi Honjo, DDS, PhD, Jolene J. Windle, PhD, J. Shin, PhD, G. D. Roodman, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 630.
https://doi.org/10.1182/blood.V106.11.630.630
Published: 2005